LGND
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) announced that it will report second quarter 2026...
Article Summary
HOLD- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) announced that it will report second quarter 2026 financial results on Thursday, August 6, 2026, with Ligand Pharmaceuticals, holding a conference call beginning at 8:30 a.m.
- Eastern time to discuss results and provide general business update.
- Ligand is a leading royalty aggregator partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs with economic interests in more than 200 development and commercial-stage assets.
- The company also licenses its proprietary technologies, Captisol® and NITRICIL™ to support drug development and formulation across its global partner network.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 51.2% | 25% | 100.0 ptsExceptional (51.2%) - Hypergrowth |
| EPS Growth Next 5Y ? | 19.4% | 25% | 50.0 ptsMeets Minimum (19.4%) - Passes screener |
| Target Price Upside ? | 7.2% | 20% | 35.0 ptsBelow Screener (7.2%) - Target: $323.30 vs Current: $301.66 |
| Gross Margin % ? | 83.4% | 15% | 100.0 ptsExceptional (83.4%) - Strong pricing power |
| Drawdown from 52-Wk High ? | -7.7% | 15% | 20.0 ptsBarely a Dip (-7.7%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About LGND
- Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide.
- It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma.
- The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes.
- In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis.
- Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder.
- The company was incorporated in 1987 and is based in Jupiter, Florida.